{"success":true,"data":{"pressRelease":{"id":"89016","rtpr_id":"nGNX7LzxhT","ticker":"FEED","exchange":"NASDAQ","all_tickers":["FEED"],"title":"ENvue Medical Appoints Chairman of the Board and New Directors, Bringing Clinical, AI Governance and Capital Markets Expertise to Navigation Platform","author":"Globe Newswire","published_at":"2026-07-15T12:00:02.375Z","article_body":"Zeev Rotstein, M.D. Named Chairman Following Four Decades in Health System\nLeadership, Including 12 Years as Director General of Sheba Medical Center\n\nZvi Joseph and Lior Buchman Join Board, Bringing Amdocs AI Governance\nLeadership and $320 Million in Executed Financings and M&A, Respectively\n\nTYLER, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- ENvue Medical\n(https://www.globenewswire.com/Tracker?data=xP4vNmAYJiYgT_vfv18C2En8ZAINKKQWVt9ekmgfBbyo4mnFCzZ27DDmv2psGZAMUWYTs1WY1ODI7OxxW2a6bA==)\n(NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a\ncommercial-stage medical device company focused on real-time guided bedside\nfeeding tube placement, today announced that Zeev Rotstein, M.D., a current\nboard member and internationally recognized health system leader, has been\nnamed Chairman of the Board, succeeding David Johnson, who is departing the\nBoard alongside fellow director Nino Pionati. The Company also appointed Zvi\nJoseph and Lior Buchman to its Board of Directors.\n\n“We believe that Professor Rotstein's decades of clinical and operational\nleadership, combined with Mr. Joseph's expertise standing up AI governance\nframeworks at a $4 billion technology company and Mr. Buchman's track record\nexecuting more than $320 million in financings and mergers and acquisitions\n(M&A) give ENvue exactly the depth we need to build on our momentum advancing\nour navigation and AI platforms,” said Doron Besser, M.D., Chief Executive\nOfficer of ENvue Medical. “I'm energized by what this board can do for\nENvue's next chapter. I'd also like to thank Mr. Johnson and Mr. Pionati for\ntheir guidance and support during their time on our board — we're grateful\nfor their contributions and wish them continued success.”\n\nProfessor Rotstein spent 36 years at Sheba Medical Center in Tel Hashomer,\nIsrael, including 12 years as Director General, during which time the hospital\nwas consistently ranked among the world's leading medical institutions. He\nwent on to serve as Chief Executive Officer and Director General of Hadassah\nMedical Center in Jerusalem, leading major operational, strategic and\nfinancial restructuring during a period of significant organizational\ntransformation.\n\n“Over decades leading two of the world's most respected health systems, I\nsaw firsthand how much precision at the bedside matters for patients and their\nfamilies relying on every procedure to go right. That's exactly what ENvue's\ntechnology aims to deliver,” said Professor Rotstein. “I'm honored to take\non this role, and I look forward to working alongside Mr. Joseph and Mr.\nBuchman as ENvue moves into its next chapter.”\n\nMr. Joseph is Head of AI Governance, Risk & Compliance at Amdocs, Inc., where\nhe built the company's global AI governance framework following two decades as\nDeputy General Counsel. He is an independent director and Compensation\nCommittee Chair at Fabric.ai and Brenmiller Energy and holds National\nAssociation of Corporate Directors (NACD) Directorship Certification and\nCertified Information Privacy Professional (CIPP) US and EU privacy\ncredentials.\n\n“ENvue is building technology that helps clinicians do their jobs more\nsafely, and AI is becoming a bigger part of that every year,” said Mr.\nJoseph. “I've spent my career helping organizations govern fast-moving\ntechnology responsibly, and I'm looking forward to bringing that experience to\nENvue's board as the company continues to grow.”\n\nMr. Buchman is a finance executive with more than 20 years leading corporate\nfinance, fundraising and M&A for venture-backed technology and medical device\ncompanies. He currently serves as Fractional Chief Financial Officer at\nERBProximo, and previously served as CEO of Integra Holdings and CFO of\nOrpheus Medical Ltd. (acquired by Intuitive) and Sightline Technologies\n(acquired by Stryker). He has served as a board director for 12 companies in\nhis career and is a Certified Public Accountant.\n\n“ENvue has the clinical validation and commercial traction that most medical\ndevice companies spend years trying to reach. I'm looking forward to\nsupporting that momentum with the financial and capital markets experience I\nbring to the board,” said Mr. Buchman.\n\nAbout ENvue Medical, Inc.\nENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company\nspecializing in the advancement of intelligent, non-invasive solutions for\nenteral care across clinical and home care settings. Headquartered in Tyler,\nTexas, with research and development in Tel-Aviv and Nesher, Israel, the\nCompany focuses on two distinct technology platforms:\n* ENvue™ Navigation Platform, developed and operated by ENvue Medical Inc.,\nwith offices in Arlington Heights, Illinois, and Tel-Aviv, Israel, is a\nminimally invasive electromagnetic navigation system intended to assist\nclinicians in placing feeding tubes into the gastrointestinal tract. FDA\n510(k) cleared for adult use, ENvue provides real-time bedside visualization\nof tube movement and supports informed decision-making during the placement\nprocedure. Future platform expansion may include pediatric and vascular access\napplications.\n* ENvue Medical aims to advance standards in non-invasive therapy and\nminimally invasive navigation, with a commitment to patient safety, clinical\nusability, and technology innovation across a range of healthcare\nenvironments.\n* Acoustic-based therapeutic technologies, including PainShield® and\nUroShield®, which utilize proprietary low-intensity surface acoustic wave\n(SAW) technology. These devices are intended for use in home or care settings\nand are designed to treat pain, reduce bacterial colonization, and disrupt\nbiofilms.\nForward-Looking Statements\nThis press release contains “forward-looking statements.” Such statements\nmay be preceded by the words “intends,” “may,” “will,”\n“plans,” “expects,” “anticipates,” “projects,” “predicts,”\n“estimates,” “aims,” “believes,” “hopes,” “potential,” or\nsimilar words. These forward-looking statements include, but are not limited\nto: statements regarding the adoption and implementation of ENvue Medical’s\nplatforms, anticipated commercial expansion, growth, scalability, and\nimplementation of ENvue Medical’s products, the success of ENvue’s\nprograms, market interest in the Company’s technology, and future\nexpectations for strategic growth. For example, ENvue is using forward-looking\nstatements when it discusses that the additions and changes to the Board give\nENvue exactly the depth it needs to build on its momentum advancing its\nnavigation and AI platforms. Forward-looking statements are not guarantees of\nfuture performance, are based on certain assumptions, and are subject to\nvarious known and unknown risks and uncertainties, many of which are beyond\nthe Company’s control and cannot be predicted or quantified; consequently,\nactual results may differ materially from those expressed or implied by such\nforward-looking statements. Such risks and uncertainties include, without\nlimitation: (i) market acceptance of the Company’s existing and new\nproducts; (ii) clinical performance and operational outcomes; (iii) delays or\ncomplications in product implementation; (iv) intense competition in the\nmedical device industry; (v) product liability or performance issues; (vi)\nlimitations in manufacturing or supply chain capabilities; (vii) reimbursement\nlimitations; (viii) intellectual property protection; (ix) healthcare\nregulatory changes in the U.S. and abroad; and (x) the need for additional\ncapital. More detailed information about the Company and the risk factors that\nmay affect the realization of forward-looking statements is set forth in the\nCompany’s filings with the Securities and Exchange Commission (“SEC”),\nincluding the Company’s Annual Report on Form 10-K, Quarterly Reports on\nForm 10-Q, and Current Reports on Form 8-K. Investors and security holders are\nurged to read these documents free of charge at: www.sec.gov. The Company\nassumes no obligation to publicly update or revise its forward-looking\nstatements as a result of new information, future events, or otherwise, except\nas required by law.\n\nInvestor Contact:\nKCSA Strategic Communications\nValter Pinto, Managing Director\nPH: (212) 896-1254\nenvue@kcsa.com\n\nMedia Contact:\nKCSA Strategic Communications\nMichaela Fawcett, Senior Account Director\nPH: (978) 995-4683\nenvue@kcsa.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/e0a97028-a7c3-4dd6-a13f-a55e43617883)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7LzxhT","title":"ENvue Medical Appoints Chairman of the Board and New Directors, Bringing Clinical, AI Governance and Capital Markets Expertise to Navigation Platform","author":"Globe Newswire","ticker":"FEED","created":"2026-07-15T12:00:02.375Z","tickers":["FEED"],"exchange":"NASDAQ","article_body":"Zeev Rotstein, M.D. Named Chairman Following Four Decades in Health System\nLeadership, Including 12 Years as Director General of Sheba Medical Center\n\nZvi Joseph and Lior Buchman Join Board, Bringing Amdocs AI Governance\nLeadership and $320 Million in Executed Financings and M&A, Respectively\n\nTYLER, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- ENvue Medical\n(https://www.globenewswire.com/Tracker?data=xP4vNmAYJiYgT_vfv18C2En8ZAINKKQWVt9ekmgfBbyo4mnFCzZ27DDmv2psGZAMUWYTs1WY1ODI7OxxW2a6bA==)\n(NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a\ncommercial-stage medical device company focused on real-time guided bedside\nfeeding tube placement, today announced that Zeev Rotstein, M.D., a current\nboard member and internationally recognized health system leader, has been\nnamed Chairman of the Board, succeeding David Johnson, who is departing the\nBoard alongside fellow director Nino Pionati. The Company also appointed Zvi\nJoseph and Lior Buchman to its Board of Directors.\n\n“We believe that Professor Rotstein's decades of clinical and operational\nleadership, combined with Mr. Joseph's expertise standing up AI governance\nframeworks at a $4 billion technology company and Mr. Buchman's track record\nexecuting more than $320 million in financings and mergers and acquisitions\n(M&A) give ENvue exactly the depth we need to build on our momentum advancing\nour navigation and AI platforms,” said Doron Besser, M.D., Chief Executive\nOfficer of ENvue Medical. “I'm energized by what this board can do for\nENvue's next chapter. I'd also like to thank Mr. Johnson and Mr. Pionati for\ntheir guidance and support during their time on our board — we're grateful\nfor their contributions and wish them continued success.”\n\nProfessor Rotstein spent 36 years at Sheba Medical Center in Tel Hashomer,\nIsrael, including 12 years as Director General, during which time the hospital\nwas consistently ranked among the world's leading medical institutions. He\nwent on to serve as Chief Executive Officer and Director General of Hadassah\nMedical Center in Jerusalem, leading major operational, strategic and\nfinancial restructuring during a period of significant organizational\ntransformation.\n\n“Over decades leading two of the world's most respected health systems, I\nsaw firsthand how much precision at the bedside matters for patients and their\nfamilies relying on every procedure to go right. That's exactly what ENvue's\ntechnology aims to deliver,” said Professor Rotstein. “I'm honored to take\non this role, and I look forward to working alongside Mr. Joseph and Mr.\nBuchman as ENvue moves into its next chapter.”\n\nMr. Joseph is Head of AI Governance, Risk & Compliance at Amdocs, Inc., where\nhe built the company's global AI governance framework following two decades as\nDeputy General Counsel. He is an independent director and Compensation\nCommittee Chair at Fabric.ai and Brenmiller Energy and holds National\nAssociation of Corporate Directors (NACD) Directorship Certification and\nCertified Information Privacy Professional (CIPP) US and EU privacy\ncredentials.\n\n“ENvue is building technology that helps clinicians do their jobs more\nsafely, and AI is becoming a bigger part of that every year,” said Mr.\nJoseph. “I've spent my career helping organizations govern fast-moving\ntechnology responsibly, and I'm looking forward to bringing that experience to\nENvue's board as the company continues to grow.”\n\nMr. Buchman is a finance executive with more than 20 years leading corporate\nfinance, fundraising and M&A for venture-backed technology and medical device\ncompanies. He currently serves as Fractional Chief Financial Officer at\nERBProximo, and previously served as CEO of Integra Holdings and CFO of\nOrpheus Medical Ltd. (acquired by Intuitive) and Sightline Technologies\n(acquired by Stryker). He has served as a board director for 12 companies in\nhis career and is a Certified Public Accountant.\n\n“ENvue has the clinical validation and commercial traction that most medical\ndevice companies spend years trying to reach. I'm looking forward to\nsupporting that momentum with the financial and capital markets experience I\nbring to the board,” said Mr. Buchman.\n\nAbout ENvue Medical, Inc.\nENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company\nspecializing in the advancement of intelligent, non-invasive solutions for\nenteral care across clinical and home care settings. Headquartered in Tyler,\nTexas, with research and development in Tel-Aviv and Nesher, Israel, the\nCompany focuses on two distinct technology platforms:\n* ENvue™ Navigation Platform, developed and operated by ENvue Medical Inc.,\nwith offices in Arlington Heights, Illinois, and Tel-Aviv, Israel, is a\nminimally invasive electromagnetic navigation system intended to assist\nclinicians in placing feeding tubes into the gastrointestinal tract. FDA\n510(k) cleared for adult use, ENvue provides real-time bedside visualization\nof tube movement and supports informed decision-making during the placement\nprocedure. Future platform expansion may include pediatric and vascular access\napplications.\n* ENvue Medical aims to advance standards in non-invasive therapy and\nminimally invasive navigation, with a commitment to patient safety, clinical\nusability, and technology innovation across a range of healthcare\nenvironments.\n* Acoustic-based therapeutic technologies, including PainShield® and\nUroShield®, which utilize proprietary low-intensity surface acoustic wave\n(SAW) technology. These devices are intended for use in home or care settings\nand are designed to treat pain, reduce bacterial colonization, and disrupt\nbiofilms.\nForward-Looking Statements\nThis press release contains “forward-looking statements.” Such statements\nmay be preceded by the words “intends,” “may,” “will,”\n“plans,” “expects,” “anticipates,” “projects,” “predicts,”\n“estimates,” “aims,” “believes,” “hopes,” “potential,” or\nsimilar words. These forward-looking statements include, but are not limited\nto: statements regarding the adoption and implementation of ENvue Medical’s\nplatforms, anticipated commercial expansion, growth, scalability, and\nimplementation of ENvue Medical’s products, the success of ENvue’s\nprograms, market interest in the Company’s technology, and future\nexpectations for strategic growth. For example, ENvue is using forward-looking\nstatements when it discusses that the additions and changes to the Board give\nENvue exactly the depth it needs to build on its momentum advancing its\nnavigation and AI platforms. Forward-looking statements are not guarantees of\nfuture performance, are based on certain assumptions, and are subject to\nvarious known and unknown risks and uncertainties, many of which are beyond\nthe Company’s control and cannot be predicted or quantified; consequently,\nactual results may differ materially from those expressed or implied by such\nforward-looking statements. Such risks and uncertainties include, without\nlimitation: (i) market acceptance of the Company’s existing and new\nproducts; (ii) clinical performance and operational outcomes; (iii) delays or\ncomplications in product implementation; (iv) intense competition in the\nmedical device industry; (v) product liability or performance issues; (vi)\nlimitations in manufacturing or supply chain capabilities; (vii) reimbursement\nlimitations; (viii) intellectual property protection; (ix) healthcare\nregulatory changes in the U.S. and abroad; and (x) the need for additional\ncapital. More detailed information about the Company and the risk factors that\nmay affect the realization of forward-looking statements is set forth in the\nCompany’s filings with the Securities and Exchange Commission (“SEC”),\nincluding the Company’s Annual Report on Form 10-K, Quarterly Reports on\nForm 10-Q, and Current Reports on Form 8-K. Investors and security holders are\nurged to read these documents free of charge at: www.sec.gov. The Company\nassumes no obligation to publicly update or revise its forward-looking\nstatements as a result of new information, future events, or otherwise, except\nas required by law.\n\nInvestor Contact:\nKCSA Strategic Communications\nValter Pinto, Managing Director\nPH: (212) 896-1254\nenvue@kcsa.com\n\nMedia Contact:\nKCSA Strategic Communications\nMichaela Fawcett, Senior Account Director\nPH: (978) 995-4683\nenvue@kcsa.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/e0a97028-a7c3-4dd6-a13f-a55e43617883)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-07-15T12:00:02.574940383Z","server_sent_at_ms":1784116802574},"received_at":"2026-07-15T12:00:02.678Z","source_url":"https://www.globenewswire.com/news-release/2026/07/15/3327653/0/en/ENvue-Medical-Appoints-Chairman-of-the-Board-and-New-Directors-Bringing-Clinical-AI-Governance-and-Capital-Markets-Expertise-to-Navigation-Platform.html"},"analysis":{"id":"78070","press_release_id":"89016","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"board_change","narrative":"ENvue Medical appointed Zeev Rotstein, M.D. as Chairman of the Board, succeeding David Johnson, who is departing alongside fellow director Nino Pionati.\n\nThe company also added Zvi Joseph and Lior Buchman to the board, bringing expertise in AI governance and capital markets respectively, with Buchman having executed over $320 million in financings.\n\nCEO Doron Besser emphasized that the new board composition provides the necessary depth to advance the company's navigation and AI platforms.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Board refresh adds heavyweight clinical, AI, and capital markets expertise as ENvue advances commercialization."},"keyFigures":{"customDimensions":{"buchman_financings":"more than $320 million","amdocs_market_cap_reference":"$4 billion","rotstein_sheba_tenure_years":12}},"quotedText":"We believe that Professor Rotstein's decades of clinical and operational leadership, combined with Mr. Joseph's expertise standing up AI governance frameworks at a $4 billion technology company and Mr. Buchman's track record executing more than $320 million in financings and mergers and acquisitions (M&A) give ENvue exactly the depth we need to build on our momentum advancing our navigation and AI platforms","namedEntities":{"people":[{"name":"Zeev Rotstein","role":"Chairman of the Board"},{"name":"David Johnson","role":"Departing Director"},{"name":"Nino Pionati","role":"Departing Director"},{"name":"Zvi Joseph","role":"New Director"},{"name":"Lior Buchman","role":"New Director"},{"name":"Doron Besser","role":"CEO"}],"products":["ENvue Navigation Platform","PainShield","UroShield"],"companies":[{"name":"ENvue Medical","ticker":"FEED"},{"name":"Sheba Medical Center"},{"name":"Hadassah Medical Center"},{"name":"Amdocs, Inc."},{"name":"Intuitive"},{"name":"Stryker"}],"dollarAmounts":[{"amount":"$320 million","context":"Lior Buchman's track record in financings and M&A"}]},"materialImpact":{"score":3,"reasoning":"Appointment of a high-profile Chairman with decades of health system leadership and two specialized directors (AI Governance, Capital Markets) significantly strengthens the board during the company's commercialization phase."},"tickerRelevance":{"others":[],"primary":"FEED"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"board_refresh_with_expertise","sectorWeight":"health_care"}},"event_type":"board_change","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"ENvue Medical appointed Zeev Rotstein, M.D. as Chairman of the Board, succeeding David Johnson, who is departing alongside fellow director Nino Pionati.\n\nThe company also added Zvi Joseph and Lior Buchman to the board, bringing expertise in AI governance and capital markets respectively, with Buchman having executed over $320 million in financings.\n\nCEO Doron Besser emphasized that the new board composition provides the necessary depth to advance the company's navigation and AI platforms.","key_figures":{"customDimensions":{"buchman_financings":"more than $320 million","amdocs_market_cap_reference":"$4 billion","rotstein_sheba_tenure_years":12}},"named_entities":{"people":[{"name":"Zeev Rotstein","role":"Chairman of the Board"},{"name":"David Johnson","role":"Departing Director"},{"name":"Nino Pionati","role":"Departing Director"},{"name":"Zvi Joseph","role":"New Director"},{"name":"Lior Buchman","role":"New Director"},{"name":"Doron Besser","role":"CEO"}],"products":["ENvue Navigation Platform","PainShield","UroShield"],"companies":[{"name":"ENvue Medical","ticker":"FEED"},{"name":"Sheba Medical Center"},{"name":"Hadassah Medical Center"},{"name":"Amdocs, Inc."},{"name":"Intuitive"},{"name":"Stryker"}],"dollarAmounts":[{"amount":"$320 million","context":"Lior Buchman's track record in financings and M&A"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-15T14:14:53.080Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"board_refresh_with_expertise","sectorWeight":"health_care"}},"durationMs":145197,"modelName":"glm-4.7"}}